Globally, at least 913,000 people are diagnosed with prostate cancer each year, accounting for 13.8% of new cancer cases in men. Of these approximately 385,500 new cases were identified in 2008 in Europe alone, making prostate cancer a major cause of morbidity and mortality in Europe.1
The Prostate Cancer Knowledge Centre is an interactive resource which aims to provide healthcare professionals, including oncologists, with the latest information in the field of prostate cancer (PCa). With information on epidemiology, detection and the available treatment and management options for hormone-sensitive and castration-resistant prostate cancer, this is a must-view resource for oncologists who are involved in the management of men with prostate cancer.
Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127(12):2893–2917.
Soft Tissue Sarcomas (STS) are malignant (cancerous) tumors that develop in tissues which connect, support, or surround other structures and organs of the body. Muscles, tendons (bands of fiber that connect muscles to bones), fibrous tissues, fat, blood vessels, nerves, and synovial tissues are types of soft tissue.
Management of soft tissue sarcoma depends on the stage of disease and histological subtype.1 Surgery is the mainstay of treatment for patients with localised disease and is often curative. However, as recurrence is likely to occur when tumour cells remain after surgery, adjuvant radiotherapy is often also considered, especially for patients with intermediate or high-grade tumours. Radiotherapy, uses high energy rays to help cure cancers, is also often administered for patients in whom surgery is inappropriate or who decline surgery.1
For soft tissue sarcomas, the specialist healthcare professional may recommend radiotherapy to shrink sarcomas before surgery, help stop the sarcoma returning after surgery, to help slow the growth rate of advanced sarcomas and help relieve symptoms.
Discover classification of sarcomas by histopathology, look at prevalence and more by visiting the The Soft Tissue Sarcoma Knowledge Centre.
. Clark MA, Fisher C et al. (2005) “Soft-tissue sarcomas in adults.” N Engl JMed 353(7): 701–11.
Suma Kumar,Guy's and St Thomas' NHS Foundation Trust, London, UK Richard Leach,Consultant Respiratory Physicians, Guy's and St Thomas' NHS Foundation Trust, London, UK
Case History A 68-year-old man presented with a four-week history of left-sided, dull, aching chest pain. He had known ischaemic heart disease, previous coronary artery bypass grafting, chronic obstructive pulmonary disease and treated duodenal ulceration.
Oni Choudhury,Guy's and St Thomas' NHS Foundation Trust, London, UK Richard Leach,Consultant Respiratory Physicians, Guy's and St Thomas' NHS Foundation Trust, London, UK
Case History A 62-year-old woman presented with a 2-3-month history of breathlessness, non-productive cough, weight loss, lethargy and ankle oedema. Her exercise tolerance was limited to 50 yards by breathlessness.
... adults in the Western world. About three quarters of patients diagnosed with chronic lymphocytic leukaemia are over 55 years old. The diagnosis of chronic lymphocytic leukaemia is often incidental, so it is important to consider it in older patients. Molecular profiling of the disease with immunophenotyping and cytogenetic analysis can provide important prognostic information, as well as informing treatment decisions. Although most patients eventually need treatment for chronic lymphocytic leukaemia, they may be in the care of their general practitioners with stable disease for many years before treatment becomes necessary. It is important to be aware of the course of the disease, as well as the possible complications.
... urologists, and nuclear medicine specialists.
The goal of this activity is to provide a foundational overview of the role of radionuclide therapy in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Upon completion of this activity, participants will be able to: Compare and contrast alpha and beta radionuclide therapy for mCRPC in terms of their mechanisms of action, safety, efficacy, and impact on patient outcomes, summarize the clinical safety and efficacy data of radionuclide therapy for the treatment and management of patients with mCRPC and identify when targeted radionuclide therapy is an appropriate treatment option for patients with CRPC and how it should be incorporated into the CRPC treatment paradigm
A Pilot. Randomised Controlled study. Early geriatric assessment and tailored treatment applied to patients with widespread Non Small Cel lung Cancer (NSCLC). On the day of planning the oncologic treatment Comprehensive Geriatric Assessment (CGA) will be offered to patients aged 60 and up. Based on the CGA a tailored..
... multidisciplinary intervention is planned with the patients. The study aim is to test different screening methods to find the best suited method to select the frail geriatric patients in order to be able to select the frail patients in a planned later study, estimate the effect of CGA on these patients in order to be able to calculate the needed number of patients and to estimate the time consumption in this latter study . The hypothesis is that the screening method G8 is superior to Performance Status(PS) and clinical oncologist´ evaluation and that CGA improves survival amongst Patients aged 60 or more with NSCLC and prevents hospitalisation and complications to the oncologic treatment.
In the proposed project we will asses whether changes in expression of selected circulating microRNAs in serum could comprise a sensitive and specific biomarker of cardiotoxicity in cancer patients treated with anthracyclines based chemotherapy.